Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
Date:10/7/2010

ts Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed.  In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo.  The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo.  In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo.  Most common adverse events >20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain.  Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo.  Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding.  In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care,
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- "Whether it,s our family, our friends, all of ... a single sentence, Dr. Anthony Coyle , senior ... Centers for Therapeutic Innovation (CTI), sums up what ... biopharmaceutical companies. CTI,s unique model allows ... and the National Institutes of Health (NIH) to bridge ...
(Date:3/26/2015)... YORK , March 26, 2015 ... the average American consumer. However, a new survey ... various ailments from the common cold to diabetes, ... The research, conducted by the Private Label ... on over-the-counter healthcare products, including those essential for ...
(Date:3/26/2015)... Research and Markets ( ... "Global Smart Wearable Healthcare Devices and Services ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The analysts forecast ... market to grow at a CAGR of 30.42% ... covers the present scenario and the growth prospects ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Consumers can keep over-the-counter medicine affordable by using store brands 2Global Smart Wearable Healthcare Devices and Services Market 2015-2019 WITH Apple, At&T, Ee, Google, Samsung, Sprint, Telefonica & T-Mobile Dominating 2
... WOODCLIFF LAKE, N.J., Nov. 3, 2010 Par Pharmaceutical Companies, ... the third quarter ended September 30, 2010. For ... total revenues of $234.4 million and income from continuing operations ... included a $2.0 milestone payment to Tris Pharma, Inc., a ...
... 2010 Regado Biosciences, Inc., a privately held company ... agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior ... at the American College of Chest Physicians (ACCP) Coagulation ... Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Third Quarter 2010 Results 2Par Pharmaceutical Companies Reports Third Quarter 2010 Results 3Par Pharmaceutical Companies Reports Third Quarter 2010 Results 4Par Pharmaceutical Companies Reports Third Quarter 2010 Results 5Par Pharmaceutical Companies Reports Third Quarter 2010 Results 6Par Pharmaceutical Companies Reports Third Quarter 2010 Results 7Par Pharmaceutical Companies Reports Third Quarter 2010 Results 8Par Pharmaceutical Companies Reports Third Quarter 2010 Results 9Par Pharmaceutical Companies Reports Third Quarter 2010 Results 10Par Pharmaceutical Companies Reports Third Quarter 2010 Results 11Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 2Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 3
(Date:3/27/2015)... March 27, 2015 “ VXi BlueParott ... its monthly Tech Report, which features the latest and ... technology expert and special reporter for NewsWatch, conducted the ... advanced noise-cancelling headset, eliminating 90% of ambient noise. , ... texts and emails are important to any professional, voice ...
(Date:3/27/2015)... In light of two lawsuits that ... District Court, District of Massachusetts; and case number 2:15-cv-00709PD, ... Pennsylvania), the San Diego personal injury lawyers of The ... that they are available to investigate potential birth ... prescribed Zofran while pregnant and who gave birth to ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Elfster.com, the ... addition of its bucket list generator capabilities to its ... course, refers to a list that one creates of ... the 2007 movie of the same name. Nowadays ... way to memorialize their summer achievements. , "We are ...
(Date:3/26/2015)... San Diego (PRWEB) March 26, 2015 ... to advance health and wellness for the poor and ... the application period for its annual $1 million award, ... is excited to announce the 2015 round of our ... "We've seen and supported some incredibly creative and ambitious ...
(Date:3/26/2015)... 26, 2015 The American College of Traditional ... the topics of the DAOM Program as well as Marketing ... Webinar will be hosted by Dr. Carla Wilson, who will ... steps on how to prepare for the spring quarter. The ... March 27, April 1 and April 3. Attendees can log ...
Breaking Medicine News(10 mins):Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2Health News:Plans for Bucket List Generator - Just In Time for Summer - Announced by Elfster 2Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2Health News:ACTCM Announces Upcoming Webinars 2
... Cellmark Inc.,(Nasdaq: ORCH ), a leading worldwide provider ... for the fourth quarter and,full year of 2007., ... the fourth,quarter of 2007 compared to $14.9 million for ... 2007, revenues were $60.3 million compared to $56.9,million for ...
... The International,Society for CNS Clinical Trials ... in Washington, DC, February 25-27. This organization,involves ... of the pharmaceutical industry, and governmental,drug-regulatory bodies ... safety,of drugs used to treat psychiatric and ...
... Health Net,s Roger and Erika Greaves; CNN,s ... of Humanity Award, SHERMAN OAKS, Calif., March 5 ... prevent pediatric,burns and to heal severely burned children, celebrated its ... on Feb. 21. The event,was attended by more than 700 ...
... N.J., March 5 Besler,& Company, Inc., a ... agreed to pay the United States $2.875 million, ... federal Medicare program, the,Justice Department announced today., ... company counseled hospital clients to improperly,increase charges to ...
... ten elderly adults on Medicare reports drinking more alcohol ... Brandeis University. , Even though alcohol problems are ... older adults are consuming alcohol in amounts that exceed ... at Brandeis Universitys Heller School for Social Policy and ...
... Answer That Question, BREA, Calif., March 5 ... site in the United States, now,helps pet owners ... are with a quick and humorous online Canine ... gauges pet owner,responses to determine their dog,s brain ...
Cached Medicine News:Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 9Health News:FDA Warning of Suicidal Risk Associated with Antidepressants in Juveniles and Young Adults Reviewed at Recent ISCTM Meeting 2Health News:Children's Burn Foundation's Benefit Raises More Than $875,000 for Burn Survivors and Prevention 2Health News:Children's Burn Foundation's Benefit Raises More Than $875,000 for Burn Survivors and Prevention 3Health News:New Jersey Healthcare Consulting Firm to Pay U.S. $2.875 Million to Resolve Allegations of Medicare Fraud 2Health News:New study sheds light on excessive drinking among the elderly 2Health News:Is Your Dog a Canine-stein or a Bonehead? 2Health News:Is Your Dog a Canine-stein or a Bonehead? 3
... Cycler is Thermo Electron's most advanced personal ... easy to use sophisticated onboard software and ... Designed to offer performance, accuracy and simplicity ... number of customer driven features built up ...
... Design With Exceptional Performance The ... interface might be the first ... MyCycler is designed for performance. ... a premium, its small footprint ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... Faster speeds, highest precision, more user-friendliness ... concept: this is the definition of the ... years nucleic acid research has been developing ... required of PCR Systems. To keep ...
Medicine Products: